A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

This study is an open-label (all volunteers and study staff know the identity of the
assigned treatment), fixed sequence (all volunteers receive the same medication on the same
days), single and multiple-dose study to determine how metformin (a blood glucose-lowering
agent used to treat patients with diabetes) affects the pharmacokinetics (ie, how the body
affects the drug) and the pharmacodynamics (ie, how the drug affects the body) of
canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes
mellitus). The effect of canagliflozin on the pharmacokinetics and pharmacodynamics of
metformin will also be evaluated. The study will consist of 3 phases: a screening phase, an
open-label treatment phase, and an end-of-study (or follow-up) phase. Each volunteer will
participate in the study for approximately 39 days.

Inclusion Criteria:

- Volunteers must have a Body Mass Index (BMI [weight (kg) / height (m)2]) between 18.5
and 35 kg/m2, inclusive

- Volunteers must be non-smokers or non-tobacco users

Exclusion Criteria:

- History of or currently active illness that the Investigator considers to be clinically
significant and should exclude the volunteer from the study or that could interfere with
the interpretation of the study results